F2G and Shionogi announced positive Phase 3 OASIS study results where oral antifungal olorofim demonstrated non-inferiority to AmBisome® followed by standard care in invasive aspergillosis patients. The study showed similar mortality rates at Day 42 (23.8% for olorofim vs. 24.3% for AmBisome®) but with fewer drug-related side effects, especially renal events. Olorofim, if approved, would be the first new treatment with a novel mechanism in over 20 years for this serious fungal infection, offering hope for patients with limited options. The companies plan to submit data to regulators and present full results at a medical congress.
Bitcoin's price surged to nearly $65,000 following softer-than-expected U.S. inflation data for June, easing fears of Federal Reserve rate hikes. However, on-chain data reveals two main groups of investors—long-term holders who bought near last year'...
Bitcoin miners are experiencing declining revenue as the network's hash rate and mining difficulty fall, reflecting a shift of miners into AI infrastructure. Despite this stress, miners are accumulating Bitcoin, with reserves increasing by 1%, signal...
Lululemon invested in Syntetica's $30 million Series A funding to support its innovative recycling of Nylon 6 and Nylon 6,6, materials difficult to separate and reuse in textile waste. This move aligns with growing industry demand for sustainable, co...
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
